3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
10
Lymphoma
7
Lymphoma, Follicular
5
Lymphoma, Non-Hodgkin
4
Lymphoma, T-Cell, Cutaneous
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Hodgkin Disease
3
Squamous Cell Carcinoma of Head and Neck
2
Prostatic Neoplasms
2
Melanoma
2
Lymphoma, T-Cell
2
Lymphoma, Mantle-Cell
2
Carcinoma, Merkel Cell
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thrombocytosis
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sezary Syndrome
1
Sarcoma
1
Recurrence
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Neoplasm Metastasis
1
Interventions
Cyclophosphamide
8
Rituximab
7
fludarabine
6
dacetuzumab
6
fludarabine phosphate
5
blinatumomab
4
Bortezomib
4
ibrutinib
3
Melphalan
3
Lenalidomide
3
Ifosfamide
3
Etoposide
3
Dexamethasone
3
Bendamustine Hydrochloride
3
AP 1903 reagent
3
ponatinib
2
cobomarsen
2
Whole-Body Irradiation
2
Vorinostat
2
Vincristine
2
Tacrolimus
2
Prednisone
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mycophenolic Acid
2
Mesna
2
Doxorubicin
2
Carboplatin
2
Busulfan
2
Brentuximab Vedotin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Immunoproliferative Disorders
×
durvalumab
×
Lymphoid
×
Clear all
NCT02733042
2023-11-18
FUSION NHL 001
Celgene
Phase 1/2
Completed
106 enrolled
48 charts